Summarized by Masters of Longevity from Longevity Technology.
A look at a new telehealth service that uses a blood-based biological age score to guide clinician-led longevity treatment plans and follow-up.
Key Takeaways
- Deep Longevity will launch a US telehealth platform called Accrua that integrates its BloodAge report into care plans.
- BloodAge uses an AI model on routine blood tests to label individuals as faster or slower agers and is re-measured quarterly.
- Accrua will offer clinician-prescribed treatments including GLP-1 weight-loss medications, peptides, and hormone therapies via partners.
